What is Wedbush’s Estimate for NovoCure FY2026 Earnings?

NovoCure Limited (NASDAQ:NVCR) – Equities research analysts at Wedbush raised their FY2026 earnings estimates for shares of NovoCure in a report released on Monday, December 2nd. Wedbush analyst D. Nierengarten now forecasts that the medical equipment provider will post earnings of ($1.14) per share for the year, up from their previous forecast of ($1.29). Wedbush has a “Neutral” rating and a $29.00 price objective on the stock. The consensus estimate for NovoCure’s current full-year earnings is ($1.31) per share. Wedbush also issued estimates for NovoCure’s FY2027 earnings at ($0.88) EPS.

NovoCure (NASDAQ:NVCR) last posted its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.34) by $0.06. NovoCure had a negative return on equity of 41.48% and a negative net margin of 25.93%. The firm had revenue of $155.10 million during the quarter, compared to the consensus estimate of $143.95 million. During the same period last year, the company earned ($0.46) earnings per share. The business’s revenue was up 21.8% compared to the same quarter last year.

NVCR has been the topic of a number of other reports. Evercore ISI raised shares of NovoCure from an “in-line” rating to an “outperform” rating and upped their target price for the company from $18.00 to $30.00 in a report on Monday. HC Wainwright restated a “buy” rating and issued a $38.00 price objective (up previously from $30.00) on shares of NovoCure in a research note on Monday. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $30.33.

NovoCure Price Performance

Shares of NVCR opened at $26.60 on Thursday. The company has a current ratio of 1.49, a quick ratio of 1.44 and a debt-to-equity ratio of 0.27. The company’s fifty day simple moving average is $17.68 and its 200 day simple moving average is $18.64. NovoCure has a 1-year low of $11.66 and a 1-year high of $32.60. The company has a market cap of $2.88 billion, a price-to-earnings ratio of -19.00 and a beta of 0.75.

Institutional Trading of NovoCure

Several institutional investors have recently modified their holdings of the business. Nordwand Advisors LLC raised its holdings in NovoCure by 100.0% during the 3rd quarter. Nordwand Advisors LLC now owns 3,029,824 shares of the medical equipment provider’s stock worth $47,356,000 after purchasing an additional 1,514,824 shares during the last quarter. Renaissance Technologies LLC raised its stake in NovoCure by 171.9% during the second quarter. Renaissance Technologies LLC now owns 760,175 shares of the medical equipment provider’s stock worth $13,022,000 after buying an additional 480,600 shares during the last quarter. Panagora Asset Management Inc. lifted its holdings in NovoCure by 309.8% in the second quarter. Panagora Asset Management Inc. now owns 409,794 shares of the medical equipment provider’s stock valued at $7,020,000 after buying an additional 309,805 shares during the period. AQR Capital Management LLC boosted its position in NovoCure by 234.2% during the second quarter. AQR Capital Management LLC now owns 431,445 shares of the medical equipment provider’s stock valued at $7,391,000 after acquiring an additional 302,351 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in NovoCure by 56.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 419,960 shares of the medical equipment provider’s stock worth $7,194,000 after acquiring an additional 152,185 shares during the period. Institutional investors own 84.61% of the company’s stock.

NovoCure Company Profile

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua.